Addressing the Mechanism of Action for the AKT Pathway in TNBC
May 26, 2020 10:00pm
By Rebecca Dent, MD
Joyce A. O'Shaughnessy, MD, discusses the phase II plasmaMATCH trial, which investigated plasma-based molecular profiling of patients with advanced breast cancer to inform therapeutic choices.
Joyce A. O'Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, Texas Oncology, and chair of The US Oncology Network, discusses the phase II plasmaMATCH trial (NCT03182634), which investigated plasma-based molecular profiling of patients with advanced breast cancer to inform therapeutic choices.
At the 2019 San Antonio Breast Cancer Symposium, Nicholas C. Turner, MD, PhD, of the Institute of Cancer Research in the United Kingdom, presented the initial data from the plasmaMATCH study. O’Shaughnessy says this was a long-awaited, innovative trial with over 1000 women with metastatic breast cancer in the United Kingdom had serial assessment of circulating tumor DNA (ctDNA) to look for actionable mutations.
The plasmaMATCH study was a proof-of-concept trial to see if they could show clinical utility of ctDNA in patients with metastatic disease by finding a genomic alteration, then subsequently target that activating mutation with therapy. O’Shaughnessy describes this trial as precision oncology in the breast cancer setting. The trial investigators were looking at activating mutations, such as HER2, AKT, ESR1 mutations in these patients.